published meta-analysis   sensitivity analysis   studies

hydroxychloroquine in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.68 [0.22; 2.08] 0.68[0.22; 2.08]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 202010%2,497NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.86 [0.52; 1.42] 0.86[0.52; 1.42]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 202010%NAnot evaluable serious adverse eventsdetailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.89 [0.44; 1.82] 0.89[0.44; 1.82]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 202010%2,497NAnot evaluable adverse eventsdetailed resultsOut of scaleBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 20.26 [15.67; 26.20] 20.26[15.67; 26.20]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 202010%2,497NAnot evaluable0.520.01.0relative treatment effectwww.metaEvidence.org2024-03-29 11:13 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 657,832 - roots T: 290